Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -204.84% is 74% above its 4-year average of -789.37%, near the high end of its 4-year range (-2617.70%–-197.55%).
8.89% above its 12-month average of -224.84%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -43.91%.
RETURN ON ASSETS (ROA)
-204.84%
RETURN ON ASSETS (ROA) AVG TTM
-224.84%
RETURN ON ASSETS (ROA) AVG 3Y
-332.29%
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+8.89%
CURRENT VS 3Y AVG
+38.36%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-535.36%
vs the sector median at left
Medicus Pharma Ltd. Common Stock
Market Cap
$10.10M
Return on Assets (ROA)
-204.84%
TTM Avg
-224.84%
3Y Avg
-332.29%
5Y Avg
N/A
Market Cap
$10.18M
Return on Assets (ROA)
-148.79%
TTM Avg
-109.24%
3Y Avg
-211.74%
5Y Avg
-146.61%
Market Cap
$9.98M
Return on Assets (ROA)
-57.74%
TTM Avg
-114.78%
3Y Avg
-140.32%
5Y Avg
-142.57%
Market Cap
$9.97M
Return on Assets (ROA)
-149.72%
TTM Avg
-86.94%
3Y Avg
-66.39%
5Y Avg
-60.64%
Market Cap
$9.92M
Return on Assets (ROA)
-52.23%
TTM Avg
-58.24%
3Y Avg
-82.00%
5Y Avg
-104.09%
Market Cap
$9.79M
Return on Assets (ROA)
-73.89%
TTM Avg
-61.17%
3Y Avg
-50.83%
5Y Avg
-128.36%
Market Cap
$11.13M
Return on Assets (ROA)
N/A
TTM Avg
-37.02%
3Y Avg
-41.41%
5Y Avg
-41.74%
Market Cap
$10.52M
Return on Assets (ROA)
N/A
TTM Avg
-21.71%
3Y Avg
-73.35%
5Y Avg
-116.85%
Market Cap
$9.66M
Return on Assets (ROA)
-115.57%
TTM Avg
-131.41%
3Y Avg
-121.81%
5Y Avg
-149.86%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Medicus Pharma Ltd. Common Stock (MDCX) | $10.10M | -204.84% | -224.84% | -332.29% | N/A |
| Tvardi Therapeutics, Inc. (TVRD)vs › | $10.18M | -148.79% | -109.24% | -211.74% | -146.61% |
| Valion Bio, Inc. (VBIO)vs › | $9.98M | -57.74% | -114.78% | -140.32% | -142.57% |
| Senti Biosciences, Inc. (SNTI)vs › | $9.97M | -149.72% | -86.94% | -66.39% | -60.64% |
| Satellos Bioscience Inc. (MSLE)vs › | $9.92M | -52.23% | -58.24% | -82.00% | -104.09% |
| Ainos, Inc. (AIMD)vs › | $9.79M | -73.89% | -61.17% | -50.83% | -128.36% |
| CytoMed Therapeutics Limited (GDTC)vs › | $11.13M | N/A | -37.02% | -41.41% | -41.74% |
| Polyrizon Ltd. (PLRZ)vs › | $10.52M | N/A | -21.71% | -73.35% | -116.85% |
| NeuroOne Medical Technologies Corporation (NMTC)vs › | $9.66M | -115.57% | -131.41% | -121.81% | -149.86% |
| MetaVia Inc. (MTVA)vs › | $9.62M | -108.85% | -94.23% | -71.21% | -107.74% |
ROA
-204.8%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -252.12% |
| 2024-12-31 | -197.55% |
| 2023-12-31 | -280.75% |
| 2022-12-31 | -598.75% |
| 2021-12-31 | -2617.70% |
